Targeting the Fas/Fas ligand pathway in cancer

  • Darren I. O'Brien
  • , Ken Nally
  • , Raymond G. Kelly
  • , Terrence M. O'Connor
  • , Ferghus Shanahan
  • , Joe O'Connell

Research output: Contribution to journalReview articlepeer-review

Abstract

Fas is a transmembrane receptor that can induce apoptosis after cross-linking with either agonistic antibodies or with Fas ligand (FasL). Although originally described as an important regulator of peripheral immune homeostasis, accumulating evidence suggests that the Fas/FasL system plays an important role in tumour development. In addition to its proapoptotic functions, accumulating evidence demonstrates that Fas can activate numerous nonapoptotic signalling pathways, and that activation of these pathways can result in increased tumourigenicity and metastasis. This review summarises the current understanding of the Fas/FasL system in tumorigenesis and discusses attempts to utilise the Fas/FasL system in the treatment of cancer.

Original languageEnglish
Pages (from-to)1031-1044
Number of pages14
JournalExpert Opinion on Therapeutic Targets
Volume9
Issue number5
DOIs
Publication statusPublished - Oct 2005

Keywords

  • Apoptosis
  • Chemotherapy
  • Drug resistance
  • Fas ligand/CD95L
  • Fas/CD95
  • Inflammation
  • Interferon (IFN)-γ

Fingerprint

Dive into the research topics of 'Targeting the Fas/Fas ligand pathway in cancer'. Together they form a unique fingerprint.

Cite this